123 related articles for article (PubMed ID: 21472182)
1. Radical arylation of tyrosine and its application in the synthesis of a highly selective neurotensin receptor 2 ligand.
Pratsch G; Unfried JF; Einsiedel J; Plomer M; Hübner H; Gmeiner P; Heinrich MR
Org Biomol Chem; 2011 May; 9(10):3746-52. PubMed ID: 21472182
[TBL] [Abstract][Full Text] [Related]
2. Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand.
Held C; Plomer M; Hübner H; Meltretter J; Pischetsrieder M; Gmeiner P
ChemMedChem; 2013 Jan; 8(1):75-81. PubMed ID: 23097347
[TBL] [Abstract][Full Text] [Related]
3. Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics.
Einsiedel J; Held C; Hervet M; Plomer M; Tschammer N; Hübner H; Gmeiner P
J Med Chem; 2011 Apr; 54(8):2915-23. PubMed ID: 21446649
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of novel multimeric neurotensin(8-13) analogs.
Hultsch C; Pawelke B; Bergmann R; Wuest F
Bioorg Med Chem; 2006 Sep; 14(17):5913-20. PubMed ID: 16735124
[TBL] [Abstract][Full Text] [Related]
5. Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia.
Eiselt E; Gonzalez S; Martin C; Chartier M; Betti C; Longpré JM; Cavelier F; Tourwé D; Gendron L; Ballet S; Sarret P
ACS Chem Neurosci; 2019 Nov; 10(11):4535-4544. PubMed ID: 31589400
[TBL] [Abstract][Full Text] [Related]
6. NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids.
Simeth NA; Bause M; Dobmeier M; Kling RC; Lachmann D; Hübner H; Einsiedel J; Gmeiner P; König B
Bioorg Med Chem; 2017 Jan; 25(1):350-359. PubMed ID: 27842797
[TBL] [Abstract][Full Text] [Related]
7. The signaling signature of the neurotensin type 1 receptor with endogenous ligands.
Besserer-Offroy É; Brouillette RL; Lavenus S; Froehlich U; Brumwell A; Murza A; Longpré JM; Marsault É; Grandbois M; Sarret P; Leduc R
Eur J Pharmacol; 2017 Jun; 805():1-13. PubMed ID: 28341345
[TBL] [Abstract][Full Text] [Related]
8. Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues.
Fanelli R; Floquet N; Besserer-Offroy É; Delort B; Vivancos M; Longpré JM; Renault P; Martinez J; Sarret P; Cavelier F
J Med Chem; 2017 Apr; 60(8):3303-3313. PubMed ID: 28368584
[TBL] [Abstract][Full Text] [Related]
9. Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
Munck Petersen C; Nielsen MS; Jacobsen C; Tauris J; Jacobsen L; Gliemann J; Moestrup SK; Madsen P
EMBO J; 1999 Feb; 18(3):595-604. PubMed ID: 9927419
[TBL] [Abstract][Full Text] [Related]
10. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2.
Gendron L; Perron A; Payet MD; Gallo-Payet N; Sarret P; Beaudet A
Mol Pharmacol; 2004 Dec; 66(6):1421-30. PubMed ID: 15361549
[TBL] [Abstract][Full Text] [Related]
11. Structure-based exploration of an allosteric binding pocket in the NTS1 receptor using bitopic NT(8-13) derivatives and molecular dynamics simulations.
Kling RC; Burchardt C; Einsiedel J; Hübner H; Gmeiner P
J Mol Model; 2019 Jun; 25(7):193. PubMed ID: 31209646
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear beta-catenin in inflammatory bowel disease-related oncogenesis.
Bossard C; Souazé F; Jarry A; Bezieau S; Mosnier JF; Forgez P; Laboisse CL
Peptides; 2007 Oct; 28(10):2030-5. PubMed ID: 17870207
[TBL] [Abstract][Full Text] [Related]
13. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
14. Intermolecular interactions between the neurotensin and the third extracellular loop of human neurotensin 1 receptor.
Da Costa G; Bondon A; Coutant J; Curmi P; Monti JP
J Biomol Struct Dyn; 2013 Dec; 31(12):1381-92. PubMed ID: 23140271
[TBL] [Abstract][Full Text] [Related]
15. Enantioselective syntheses of alpha-Fmoc-Pbf-[2-(13)C]-L-arginine and Fmoc-[1,3-(13)C2]-L-proline and Incorporation into the neurotensin receptor 1 ligand, NT(8-13).
Song C; Tapaneeyakorn S; Murphy AC; Butts C; Watts A; Willis CL
J Org Chem; 2009 Dec; 74(23):8980-7. PubMed ID: 19883062
[TBL] [Abstract][Full Text] [Related]
16. Identification and functional characterization of a 5-transmembrane domain variant isoform of the NTS2 neurotensin receptor in rat central nervous system.
Perron A; Sarret P; Gendron L; Stroh T; Beaudet A
J Biol Chem; 2005 Mar; 280(11):10219-27. PubMed ID: 15637074
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of neurotensin(9-13) analogues exhibiting enhanced human neurotensin receptor binding affinities.
Lundquist JT; Büllesbach EE; Dix TA
Bioorg Med Chem Lett; 2000 Mar; 10(5):453-5. PubMed ID: 10743946
[TBL] [Abstract][Full Text] [Related]
18. Impact of the proline residue on ligand binding of neurotensin receptor 2 (NTS2)-selective peptide-peptoid hybrids.
Held C; Hübner H; Kling R; Nagel YA; Wennemers H; Gmeiner P
ChemMedChem; 2013 May; 8(5):772-8. PubMed ID: 23532897
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization.
Hermans E; Octave JN; Maloteaux JM
Mol Pharmacol; 1996 Feb; 49(2):365-72. PubMed ID: 8632771
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cellular regulation of neurotensin receptor under acute and chronic agonist stimulation.
Souazé F; Forgez P
Peptides; 2006 Oct; 27(10):2493-501. PubMed ID: 16889873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
